Myriad Genetics (MYGN) Amortization of Deferred Charges (2016 - 2026)

Myriad Genetics (MYGN) has reported Amortization of Deferred Charges for 11 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 64.29% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $5.9 million (down 41.0% YoY), while the FY2025 annual figure was $7.7 million, down 18.95% from the prior year.
• Amortization of Deferred Charges retreated to $1.0 million in Q1 2026 per MYGN's latest filing, from $1.1 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.5 million in Q2 2022 and bottomed at $200000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $2.4 million across 5 years, with a median of $2.8 million in 2023.
• On a YoY basis, Amortization of Deferred Charges climbed as much as 1733.33% in 2022 and fell as far as 67.78% in 2022.
• Myriad Genetics' Amortization of Deferred Charges stood at $3.1 million in 2022, then decreased by 12.9% to $2.7 million in 2023, then advanced by 3.7% to $2.8 million in 2024, then plunged by 60.71% to $1.1 million in 2025, then dropped by 9.09% to $1.0 million in 2026.
• Business Quant data shows MYGN's Amortization of Deferred Charges at $1.0 million in Q1 2026, $1.1 million in Q4 2025, and $1.0 million in Q3 2025.